ライフサイエンスコーパス: zonisamide

1 etam, and 146 (45%) participants who started zonisamide.

2 or to receive lamotrigine, levetiracetam, or zonisamide.

3 m, and 315 participants randomly assigned to zonisamide.

4 piramate, and 1 study each of sertraline and zonisamide.

5 bound, -0.11 (0.03) mug/L/mg (P < .001); and zonisamide, -0.53 (0.14) mug/L/mg (P < .001) except for

6 ng), levetiracetam 500 mg twice per day, and zonisamide 100 mg twice per day.

7 As with valproic acid and carbamazepine, zonisamide (12.5 and 25 mg/kg) increased DA release in t

8 y, levetiracetam 20 mg/kg twice per day, and zonisamide 2.5 mg/kg twice per day.

9 to 15.71 mug/L/mg; P < .001), and 29.8% for zonisamide (40.12 mug/L/mg to 28.15 mug/L/mg; P < .001).

10 In this short-term, preliminary trial, zonisamide and hypocaloric diet resulted in more weight

11 Zonisamide and pregabalin have recently obtained licence

12 lsant mood-stabilizers, valproic acid (VPA), zonisamide, and carbamazepine, but not the typical APD h

13 ormed for all medications except sertraline, zonisamide, and fluoxetine, which are summarized narrati

14 loxetine, clonazepam, ramelteon, gabapentin, zonisamide, and yokukansan.

15 f the present study was to determine whether zonisamide, another anticonvulsant mood stabilizer, as w

16 Levetiracetam and zonisamide are licensed as monotherapy for patients with

17 s do not support the use of levetiracetam or zonisamide as first-line treatments for patients with fo

18 r levetiracetam and 1.232 (1.112, 1.307) for zonisamide at a cost-effectiveness threshold of E20 000

19 ers (AMS), valproic acid, carbamazepine, and zonisamide, but not lithium, also preferentially increas

20 and cost-effectiveness of levetiracetam and zonisamide compared with lamotrigine in people with newl

21 amotrigine (HR 1.18; 97.5% CI 0.95-1.47) but zonisamide did meet the criteria for non-inferiority in

22 etam, tiagabine, topiramate, vigabatrin, and zonisamide do not induce the metabolism of other AEDs.

23 ghts, we revealed that combined treatment of zonisamide (enhancing the GABA(A)R-a5 signaling) and gra

24 cosamide remained superior to topiramate and zonisamide for retention (P < 0.002); among third-line A

25 iramate and lacosamide were both superior to zonisamide for seizure freedom (P < 0.001), while lacosa

26 d mental states, which culminates in a novel zonisamide-granisetron cocktail therapy for potential ta

27 The zonisamide group (n = 19) had a mean weight loss of 9.2

28 Seventeen (57%) of 30 in the zonisamide group and 3 (10%) of 30 in the placebo group

29 th the last observation carried forward, the zonisamide group lost more body weight than the placebo

30 acetam (HR 1.32 [97.5% CI 1.05 to 1.66]) and zonisamide (HR 1.37 [1.08-1.73]).

31 a double-blind, placebo-controlled trial of zonisamide in individuals with AUD.

32 Zonisamide is a marketed antiepileptic drug that has ser

33 Patients were randomly assigned to receive zonisamide (n = 30) or placebo (n = 30).

34 motrigine (n=330), levetiracetam (n=332), or zonisamide (n=328).

35 am, oxcarbazepine, topiramate, brivaracetam, zonisamide, or pregabalin.

36 e lacosamide again had better retention than zonisamide (P < 0.006); there were insufficient patients

37 Zonisamide therapy was started at 100 mg/d orally, with

38 ss non-inferiority of both levetiracetam and zonisamide to lamotrigine for the primary outcome of tim

39 t loss was an adverse effect associated with zonisamide treatment in epilepsy clinical trials.

40 s index, and percent body fat estimated that zonisamide treatment over the 16-week study duration was

41 ing reduction in AUD participants undergoing zonisamide treatment.

42 Zonisamide was tolerated well, with few adverse effects.

43 controlled trial compared levetiracetam and zonisamide with lamotrigine as first-line treatment for